NCAM1 and non-small cell lung carcinoma: The prevalence of CD3−/CD56+, CD3−/NKp46+, and CD3−/NKG2D+ NK cells significantly increased in NSCLC patients in UICC stage III to IV (* p < 0.05, Figure 4A–C).